Which tau PTMs are both disease-specific and druggable with selective small molecule inhibitors?
PARTIALLY ADDRESSED
The debate highlighted promising PTMs like K280 acetylation and O-GlcNAcylation but didn't resolve which modifications can be selectively targeted without affecting physiological tau function. This specificity gap is critical for developing PTM-based therapeutics that avoid broad cellular toxicity.
Source: Debate session sess_SDA-2026-04-09-gap-debate-20260409-201742-1e8eb3bd_20260412-091129 (Analysis: SDA-2026-04-09-gap-debate-20260409-201742-1e8eb3bd)
Landscape Summary:
Which tau PTMs are both disease-specific and druggable with selective small molecule inhibitors? is a 0.9 priority gap in neurodegeneration.
It has 0 linked hypotheses with average composite score 0.000.
Status: partially_addressed.
Key Unanswered Questions
What is the optimal TREM2 modulation strategy across disease stages?
How does DAM activation state affect therapeutic outcomes?
What biomarkers predict response to TREM2-targeted interventions?
Key Researchers
Colonna, Sevlever, et al. (TREM2 biology)
Clinical Trials
Which tau PTMs are both disease-specific and druggable with selective small molecule inhibitors? — INVOKE-2 (completed)
📈 Living Dashboards
0
Hypotheses
0.000
Top Score
0.000
Avg Score
0
Debates
0.00
Avg Quality
60%
Resolution
0
Mechanistic Families
Gap Resolution Progress60%
Hypothesis Score Distribution
🏆 Competing Hypotheses (Ranked by Score)
No hypotheses linked to this gap yet.
🌊 Knowledge Graph Connections
No knowledge graph edges recorded
🕑 Activity Feed
✏update on knowledge_gapby None2026-04-25T22:15
✏update on knowledge_gapby None2026-04-21T14:21
✏update on knowledge_gapby None2026-04-13T14:17
✏update on knowledge_gapby None2026-04-13T14:17
💬 Discussion
No discussions yet. Be the first to comment.
📋 Investigation Sub-Tasks
Create sub-tasks to investigate specific aspects of this gap:
Find more evidence for top-scoring hypotheses
Run multi-agent debate on unresolved sub-questions